Unraveling mitochondrial dysfunction in polycystic ovary syndrome: Pathophysiological insights
- PMID: 40813993
- PMCID: PMC12742714
- DOI: 10.1097/JCMA.0000000000001281
Unraveling mitochondrial dysfunction in polycystic ovary syndrome: Pathophysiological insights
Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder that affects women of reproductive age. It is characterized by ovulatory dysfunction, excessive levels of androgens, and the presence of multiple cysts in the ovaries. Although the exact cause of PCOS remains uncertain, recent studies have identified mitochondrial dysfunction as a key contributing factor. Mitochondria, often described as the energy centers of the cell, are essential for producing ATP, generating reactive oxygen species (ROS), and regulating cell death pathways. A growing body of evidence shows that mitochondrial dysfunction occurs in the ovaries, skeletal muscle, and adipose tissue of individuals with PCOS. This dysfunction may play a central role in the development of the disorder by increasing oxidative stress and chronic inflammation, worsening insulin resistance, and interfering with oocyte growth and quality. This review summarizes recent progress in understanding how mitochondrial dysfunction contributes to the underlying biology of PCOS. It also explores emerging treatment strategies that aim to restore mitochondrial health, such as the use of antioxidants, therapies that specifically target mitochondria, and emerging mitochondrial replacement technologies. These approaches hold promise for reducing the symptoms and long-term complications associated with PCOS.
Keywords: Dysfunction; Mitochondria; Pathogenesis; Polycystic ovary syndrome; Reactive oxygen species.
Copyright © 2025, the Chinese Medical Association.
Conflict of interest statement
Conflicts of interest: Dr. Kuan-Hao Tsui, an editorial board member at Journal of the Chinese Medical Association, had no role in the peer review process of or decision to publish this article. The other authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.
Figures
References
-
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7. - PubMed
-
- Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. ; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–88. - PubMed
-
- Wallace DC. Mitochondrial diseases in man and mouse. Science. 1999;283:1482–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
